CRTX News and Press, Cortexyme Inc. From 11/11/21

Evidence supports P. gingivalis as a driver of Alzheimer’s in easily identified patient population Successful identification of target population and therapeutic dose inform next steps Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase ...

Cassava Sciences' Simufilam is now seen as the best hope to treat all patients in Alzheimer's disease after disappointment in Cortexyme's data. Cortexyme failed to prevent disease progression in 50% of patients on what was hopefully an upstream mechanism of action vs. Simufilam. T...

Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14 th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Bosto...

Cortexyme's Alzheimer's drug candidate atuzaginstat appears to help those in the early stages of the disease who have an active P. gingivalis infection. Some antibiotics that act as direct antioxidants may slow down cognitive decline in anyone with Alzheimer's disease at any stage. ...

Yesterday, Cortexyme (NASDAQ: CRTX) , a clinical-stage biotech, saw its shares drop by a whopping 76%. The drugmaker's stock crumbled after the company announced that the experimental Alzheimer's disease therapy, atuzaginstat, missed the co-primary endpoints of its phase 2/3 GAIN tr...

Cortexyme (NASDAQ: CRTX) stock has been hammered in response to a failed clinical trial for its experimental Alzheimer's disease treatment. The clinical-stage biotech stock immediately plummeted 75%, catching many investors by surprise. If you're new to biotech investing , t...

Drug development is often characterized as a binary event, with the release of clinical-trial data capable of sparking substantial stock moves in either direction. Wednesday provided proof of this concept. Nurix (NASDAQ:NRIX) marked one of the standout gainers on the session, rallying in the ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today,  Cortexyme  (NASDAQ: CRTX ) is among the biggest losers in the market. Shares of CRTX stock have lost 75% in a walloping in the market today. Source: Shutterstock This move comes following a rat...

Gainers: Siyata Mobile (NASDAQ:SYTA) +179%. AgriFORCE (NASDAQ:AGRI) +180%. China XD Plastics (NASDAQ:CXDC) +70%. Pasithea (NASDAQ:KTTA) +46%. Enphase (NASDAQ:ENPH) +28%. Kaival Brands (NASDAQ:KAVL) +25%. Leju Holdings (NYSE:LEJU) +24%. Volcon (NASDAQ:VLCN) +22%. Nurix (NASDAQ:NRIX) +22%. Guar...

Shares of Cortexyme (NASDAQ: CRTX) , a clinical-stage biotechnology company, are collapsing in response to a clinical trial failure. Investors upset with the results had hammered the stock 74.9% lower as of 12:14 p.m. EDT on Wednesday. Cortexyme's former lead candidate, atuzagin...